Replies to post #181019 on Biotech Values

[Double_Bagel]

ENTA—Today's announcement of the clinical advancement of EDP-239 (#msg-105063800) is probably the reason ENTA's CSO exercised options two days ago without selling the new shares.

I am not sure that I understand. Are you saying that this news was not expected soon and should cause the shares to rise quite a bit? The first milestone of $15 million is not due for quite a while, so there is no immediate benefit to the bottom line. Thanks.